To gain additional insight into the potential clinical relevance of targeting both VEGFR2
and c-MET in men with PC bone metastases, we tested the
effect of axitinib (VEGFR inhibitor) [23]
and crizotinib (c-MET inhibitor) [24], either as single agents or in combination, in an ort[r]